Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Vigil Neuroscience Inc ( (VIGL) ) just unveiled an update.
On January 23, 2025, Vigil Neuroscience announced positive results from its completed Phase 1 clinical trial of VG-3927, a small molecule TREM2 agonist, aimed at treating Alzheimer’s disease. The trial demonstrated a favorable safety and tolerability profile, along with significant pharmacokinetic and pharmacodynamic markers, supporting the drug’s advancement to a Phase 2 trial scheduled for the third quarter of 2025. This development positions VG-3927 as a promising once-daily oral therapy that could offer a more convenient treatment option for Alzheimer’s patients, potentially addressing disease progression beyond targeting amyloid plaques.
More about Vigil Neuroscience Inc
Vigil Neuroscience Inc. is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by leveraging the sentinel immune cells of the brain, microglia. The company is committed to creating precision-based therapies for neurodegenerative conditions, with a current emphasis on Alzheimer’s disease using innovative drug modalities.
YTD Price Performance: 17.51%
Average Trading Volume: 231,941
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $85.03M
For detailed information about VIGL stock, go to TipRanks’ Stock Analysis page.
